Martinsried/Munich, Germany - 18 May 2015 - Proteros biostructures GmbH ("Proteros") announced today it had achieved an important milestone in a lead discovery collaboration with Janssen Pharmaceutica NV ("Janssen") triggering an undisclosed payment to Proteros.
Proteros has collaborated with Janssen for over a decade supporting numerous projects across all therapeutic areas. The objective of this oncology focused project was for Proteros to discover potent and selective small molecule inhibitor series against a novel protein target. Based on the establishment of a de novo X-ray crystallography system, HTS screening and biophysical assay technology of the novel target Proteros delivered multiple chemical series meeting stringent compound criteria.
Dr. Peter Reinemer, Chief Operating Officer for Proteros, stated: "We are very pleased to be Janssen's partner in one of their oncology discovery programs and that we have been able to deliver new compound classes for a challenging novel drug target."
About Proteros biostructures
Proteros is a privately held company that provides services and proprietary technologies to support integrated drug discovery. Proteros uses its technical expertise, industrial processes and unique technologies for crystallography, kinetic and thermodynamic profiling and lead discovery. The platform allows structure accelerated Lead Discovery. Proteros currently provides services to more than 100 pharmaceutical and biotechnology clients in North America, Europe and Asia. For more information, visit: www.proteros.de
Contacts: For Press enquiries:
Dr. Torsten Neuefeind, CEO Katja Arnold, MC Services AG
Proteros biostructures GmbH Email: firstname.lastname@example.org
Email: email@example.com Phone: +49 89 210 228-0